Skip to main content
Midas Edge

Editas Medicine, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

EDIT$2.51-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity for the

Condensed Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 202597,866,996$10$1,655,781$—$(1,628,503)$27,288
Vesting of restricted common stock awards34,038—————
Stock-based compensation expense——2,102——2,102
Net loss————(24,982)(24,982)
Balance at March 31, 202697,901,034$10$1,657,883$—$(1,653,485)$4,408
Issuance of common stock and warrants to purchase future common stock from financing55,555,5565116,875——116,880
Exercise of stock options20,040—36——36
Stock-based compensation expense——2,193——2,193
Vesting of restricted common stock awards54,268—————
Unrealized loss on marketable debt securities———(6)—(6)
Net loss————(18,230)(18,230)
Balance at June 30, 2026153,530,898$15$1,776,987$(6)$(1,671,715)$105,281
Exercise of stock options83,445—151——151
Stock-based compensation expense——2,571——2,571
Vesting of restricted common stock awards43,619—————
Unrealized loss on marketable debt securities———(90)—(90)
Net loss————(23,393)(23,393)
Balance at September 30, 2026153,657,962$15$1,779,709$(96)$(1,695,108)$84,520
Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 202482,734,696$8$1,602,441$268$(1,468,443)$134,274
Issuance of common stock from at-the-market equity offering, net706,236—1,435——1,435
Vesting of restricted common stock awards268,604—————
Stock-based compensation expense——2,979——2,979
Unrealized loss on marketable debt securities———(180)—(180)
Net loss————(76,088)(76,088)
Balance at March 31, 202583,709,536$8$1,606,855$88$(1,544,531)$62,420
Issuance of common stock from at-the-market equity offering, net3,419,83617,184——7,185
Stock-based compensation expense——2,664——2,664
Vesting of restricted common stock awards102,894—————
Issuance of common stock under employee stock purchase plan156,159—228——228
Unrealized loss on marketable debt securities———(73)—(73)
Net loss————(53,235)(53,235)
Balance at June 30, 202587,388,425$9$1,616,931$15$(1,597,766)$19,189
Issuance of common stock from at-the-market equity offering, net5,799,178—17,147——17,147
Exercise of stock options12,130—21——21
Stock-based compensation expense——2,228——2,228
Vesting of restricted common stock awards64,688—————
Unrealized loss on marketable debt securities———(15)—(15)
Net loss————(25,117)(25,117)
Balance at September 30, 202593,264,421$9$1,636,327$—$(1,622,883)$13,453
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.